GBI Research
Global Business Intelligence

Although complexities inherent in biological drug manufacturing are creating barriers for further expans

Adam Bradbury and Rishikesh Mandilwar, Analysts at GBI Research and co-authors of the company fac
latest report

Mandilwar explains: “In order to be successful in the biosimilars sector, companies must adopt the lates

A number of biologics are set to go off patent before 2020, which presents a huge opportunity for biosi

Pricing for biosimilars is usually 30–50% lower than the innovator product. These cost advantages will

Bradbury concludes: “The biosimilar pipeline is robust, and most products are being developed for the